Hemophilia B: Symptoms, Diagnosis and Treatment

Understanding hemophilia B

Hemophilia B, also called haemophilia B, factor IX deficiency or Christmas disease, is a bleeding disorder caused by insufficient working factor IX. This clotting protein helps the body stop bleeding. Treatment and an individual emergency plan help manage the risk. ²⁸

This guide supports conversations with your hemophilia team. It is educational information, not a personal diagnosis or treatment prescription. Medicine indications were checked on 16 October 2026.

When bleeding needs urgent help

Seek emergency care after a head injury or major trauma, or for vomiting blood, coughing blood, black or bloody stools, or a sudden severe headache with confusion or vomiting. Use your local emergency number. ⁴

A person with hemophilia should not wait for visible bleeding after a head injury. Explain the diagnosis immediately to emergency staff and contact the hemophilia team so they can help coordinate treatment. If you have been trained to follow a prescribed emergency plan, follow it without delaying emergency care. Bring treatment information and medicines when feasible. New joint or muscle pain, swelling, tingling or numbness, blood in the urine, or bleeding that causes concern needs immediate advice from the hemophilia team. The same applies if bleeding occurs and the prescribed medicine is unavailable. Preventive treatment does not make these warning signs safe to ignore. If the team cannot be reached, use an urgent medical service rather than waiting for the next routine appointment. ⁴

Throat or neck swelling, difficulty breathing or swallowing, or suspected throat bleeding also needs emergency care because swelling can obstruct the airway. ³

Symptoms and severity

Bleeding in hemophilia B can last longer because clot formation is less effective; it does not mean blood necessarily flows faster from every small cut. Some important bleeds occur inside the body, especially in joints and muscles, without an obvious open wound. Bruising, prolonged bleeding after an injury, and bleeding after dental work or surgery may reveal the problem. A painful, swollen joint or a muscle that feels tight deserves attention even when the skin looks normal. In more severe disease, bleeding can happen without a clear injury. In milder disease, a substantial procedure or injury may be the first time an unusual bleeding tendency becomes apparent. Symptoms and a blood test belong together: neither the size of one bruise nor a photograph can establish the diagnosis. ²⁸

Severity describes baseline factor IX activity before treatment, rather than the level soon after an infusion. The categories below help guide care, but a mild label does not remove procedural bleeding risk. Diagnosis requires specific factor testing. Newborns naturally have lower factor IX activity, so a mildly low result may need repeating later; an actively bleeding baby still needs prompt assessment. ¹

How hemophilia B is diagnosed

Assessment starts with the personal and family bleeding history: what happened, whether it followed an injury or procedure, how long it lasted, and whether treatment was needed. A clinician also considers medicines and other conditions that could explain bleeding. Screening blood tests provide different information from a specific clotting-factor assay; one general blood result is not a complete explanation of an unusual bleeding pattern. The specialist uses the history, examination and appropriate laboratory tests together. This also helps distinguish an inherited factor deficiency from other bleeding disorders rather than assigning every unexplained bruise the same diagnosis. Keep records of important bleeding episodes and previous test results if they are available. They help the team interpret changes and plan appropriate follow-up. ³

A normal activated partial thromboplastin time, or APTT, does not exclude mild hemophilia B. When the history raises concern, the specialist may still request a factor IX activity assay. Hemophilia A involves factor VIII, whereas B involves factor IX; identifying the deficient factor matters because the treatments are not interchangeable. Desmopressin, sometimes used in hemophilia A, does not raise factor IX and is not a replacement treatment for B. ¹⁴

Inheritance and family testing

Hemophilia B usually results from a disease-causing change in the F9 gene on the X chromosome. If a mother carries one altered copy and the father does not have hemophilia B, each son has a 50% chance of inheriting the variant and having the condition, while each daughter has a 50% chance of inheriting the variant. Daughters who inherit it can also have bleeding symptoms. An affected father passes his X chromosome to every daughter and to none of his sons. These probabilities apply independently to each pregnancy; a previous child’s result does not determine the next. A new genetic change can also occur, so a family history is not required. Identifying the familial variant helps relatives receive appropriate testing and counseling. The genetic result answers an inheritance question, while factor activity and the bleeding history help assess the person’s clinical needs. Genetic counseling can explain what testing would and would not tell a family before decisions are made. ⁵

Women and girls need their own assessment

Women and girls may have hemophilia B or be symptomatic carriers, and bleeding should not be dismissed because the condition is more often recognized in boys. Heavy menstrual bleeding, prolonged bleeding after dental treatment, and bleeding around procedures are relevant symptoms to report. A factor IX activity test measures the clotting protein’s activity; a genetic test determines whether a particular F9 variant is present. A normal-range factor result does not establish that someone is not a carrier. Even relatives with the same family variant may have different factor levels and different experiences of bleeding. Women and girls with factor activity below 40% can be classified as having hemophilia, while people with higher levels can still have clinically important symptoms. Assessment should address the person’s own bleeding and future procedures, alongside questions about inheritance. Counseling and treatment planning are relevant to their health, not only to the possibility of having an affected child. ⁷

Pregnancy, birth and newborn planning

Discuss a known or possible family history before pregnancy when possible, or early in pregnancy if it has not already been assessed. Hematology, maternity and anesthesia teams can develop a coordinated plan for the pregnant person and baby. A particularly important distinction in hemophilia B is that factor IX does not rise appreciably during pregnancy in the way factor VIII often does. Advice based on hemophilia A therefore cannot simply be transferred to B. The plan should address bleeding prevention around delivery, pain-relief options, care after birth, and how the newborn will be assessed. Delivery decisions depend on the individual circumstances and require an agreed clinical plan; this guide cannot choose a delivery method. Genetic counseling can also explain reproductive and prenatal testing options without assuming that every family wants the same information or intervention. Knowing fetal sex alone does not diagnose or exclude a bleeding disorder. Ensure that the newborn-care team knows about the family history before procedures are performed. ⁸

Preventive treatment and factor IX replacement

Prophylaxis means regular treatment intended to prevent bleeding. On-demand treatment is used when a bleed occurs; a separate plan may be needed for surgery or other procedures. The difference is the goal of treatment, not simply the name of the medicine. In a randomized crossover study, 50 males with factor IX activity of 2% or less and frequent bleeding had substantially fewer bleeds during nonacog-alfa prevention than during on-demand periods. The participants were a selected group, so the study is not a prescription for everyone with a mild, moderate or severe label. BeneFIX is one nonacog-alfa replacement product. Its United States label covers routine prophylaxis from age 16, while European Union labeling covers treatment and prevention at all ages. That regional difference concerns this product’s approved use; it does not mean that children cannot receive factor IX prophylaxis. The hemophilia team chooses a regimen using the individual’s bleeding pattern, activity and response. ¹⁶

Standard half-life factor IX

Replacement treatment supplies factor IX through a vein. Rixubis, or nonacog gamma, is a recombinant factor IX product whose current United States labeling includes adults and children for prevention, bleeding treatment and perioperative care. Treatment is supervised by clinicians experienced in hemophilia, even when a trained person administers it at home. The clinical response and factor activity can be monitored to check whether the intended effect is being achieved. If bleeding is not controlled as expected, the explanation needs assessment rather than an unsupervised increase in treatment. Product labeling warns about inhibitor formation, serious allergic reactions and thrombotic complications, so the team needs to know about previous reactions and other relevant health conditions. A familiar product name does not remove the need to review those risks when circumstances change. Rixubis is not approved for immune tolerance induction, a separate specialist approach to inhibitors. ¹⁷

Ixinity, or nonacog beta, is another recombinant factor IX replacement. Its United States indication now includes children younger than 12 as well as older children and adults, covering prevention, control of bleeding and surgical care. Older online descriptions that restrict it to ages 12 and above are outdated. Pediatric care still requires individualized assessment: an all-ages indication does not mean a child should copy an adult’s treatment plan. The prescribing information calls for monitoring the clinical response and appropriate factor activity, and for investigation of an inhibitor when expected factor levels or bleeding control are not achieved. Families should be trained in the administration and storage requirements of the actual product prescribed. A change of product should come with updated instructions from the team, rather than assumptions based on another brand’s preparation or treatment schedule. ¹⁸

Extended-half-life factor IX

Extended-half-life products are designed to keep replacement factor IX in the circulation longer, but they achieve this in different ways. Alprolix, or eftrenonacog alfa, links factor IX to an Fc fragment. Its clinical program included previously treated adults and children, with treatment tailored to response; those results should not be treated as a guarantee of zero bleeding. Laboratory interpretation also matters. Some assay reagents, including kaolin-based methods, can underestimate this product’s factor activity, so the laboratory needs the product name. Evidence in previously treated people does not establish the inhibitor risk of a baby receiving factor for the first time. In the small PUPs B-LONG study of previously untreated children, an inhibitor and hypersensitivity occurred in one participant. That finding reinforces the need for careful early-exposure supervision, but a small single-product study cannot reliably rank the safety of all replacement options. ¹⁹

Idelvion, or albutrepenonacog alfa, extends persistence by linking factor IX to albumin. Current United States and European Union information includes adults and children. The body’s handling of the medicine can differ with age and between individuals, which is why reduced infusion burden is a discussion about the person’s response rather than a fixed promise attached to the brand. In the PROLONG-9FP program, previously treated patients achieved low bleeding rates with individualized prevention. A reported median spontaneous bleeding rate of zero describes the middle of the study results; it does not mean that every participant had no bleeds. Longer treatment intervals were studied under defined eligibility and stability conditions. They should not be copied from a trial summary or used to extend a prescribed interval independently. Monitoring may include clinical bleeding, factor activity and assessment for inhibitors when the expected response is not obtained. The aim is sustained protection that fits the person’s clinical circumstances. ²⁰

Rebinyn in the United States and Refixia in the European Union are brand names for nonacog beta pegol, a factor IX product modified with polyethylene glycol to prolong its activity. Current United States labeling includes prophylaxis, and the current European Union indication covers all ages. Old summaries that say Rebinyn cannot be used for routine prevention or that Refixia is restricted to ages 12 and above no longer reflect these indications. Product-specific laboratory methods are important because some assays can give misleading factor levels with this modified protein. Tell any treating hospital which replacement you use, particularly if it is unfamiliar to that laboratory. The paradigm trials support preventive efficacy in the studied populations, but they were not head-to-head comparisons against Fc-fusion or albumin-fusion products. Comparing isolated bleeding-rate figures from different programs can therefore be misleading. Selection should consider the individual’s protection, monitoring, treatment burden and locally approved options together. ²¹

Emicizumab, sold as Hemlibra, is approved for hemophilia A. It is not a factor IX deficiency treatment. ²⁷

Inhibitors and allergic reactions

An inhibitor is an antibody that reduces the effectiveness of replacement factor. In hemophilia B, an inhibitor can be associated with a serious allergic reaction. Severe allergy symptoms such as breathing difficulty or collapse require emergency help. Treatment choice is particularly specialized because activated prothrombin complex concentrate contains factor IX, which matters when an inhibitor accompanies allergy. Immune tolerance induction attempts to overcome an inhibitor through repeated exposure, but evidence in B is limited and kidney complications, including nephrotic syndrome, are a concern. It should not be presented as a routine cure. A specialist center needs to coordinate inhibitor testing, bleeding treatment and longer-term prevention. ¹⁴

Nonfactor medicines for prevention

The following United States and European Union indications were checked on 16 October 2026. Local approval, supply, funding and personal suitability are separate questions; ask your specialist service about current access.

Marstacimab: Hympavzi

Marstacimab is an antibody that blocks tissue factor pathway inhibitor, helping shift the clotting balance toward clot formation without replacing factor IX. The current United States Hympavzi label covers prevention in hemophilia B from age six, with or without factor IX inhibitors. European Union criteria differ: patients must be at least 12 and weigh at least 35 kilograms, with inhibitors, or have severe B with factor IX below 1% without inhibitors. These differences are important when reading older approval announcements or advice written for another country. The medicine is preventive treatment, not an extra-dose rescue treatment for a new bleed. Thrombosis and serious hypersensitivity are important risks, and pregnancy-related risks need specialist counseling when relevant. Before starting, the team should explain what to do for breakthrough bleeding and procedures, including which additional treatment is appropriate. Do not combine it with an old factor or bypassing-agent plan without that review. ²²

Concizumab: Alhemo

Concizumab also blocks tissue factor pathway inhibitor. In the United States, Alhemo is approved for preventive treatment from age 12 in hemophilia B with or without inhibitors; descriptions calling it inhibitor-only are outdated. European Union approval covers ages 12 and above with inhibitors, or moderate or severe B with factor IX activity of 2% or less without inhibitors. Specialist monitoring is part of using the medicine, rather than an optional addition to injections. Thrombotic events and serious allergic reactions are important risks. Additional treatment for bleeding must follow the specific plan because high or frequent doses of factor or bypassing medicines can increase clotting risk. Patients should know whom to contact if a bleed happens, an operation is planned, or the usual preventive treatment is interrupted. A withdrawn application to extend European use below age 12 did not withdraw the medicine’s existing approvals. It also does not establish a younger-child indication elsewhere. ²³

Fitusiran: Qfitlia

Fitusiran is a small interfering RNA medicine that lowers antithrombin, a protein that normally limits clotting. It is not gene therapy and does not provide factor IX. In the United States, Qfitlia is approved for routine prevention from age 12 in hemophilia B with or without inhibitors. Its boxed warnings address thrombosis and acute or recurrent gallbladder disease. Liver toxicity is another important risk, and treatment requires specialist antithrombin and liver monitoring. The prescribed plan therefore includes laboratory-guided management as well as injections. A breakthrough bleed needs the treatment approach specified for fitusiran; simply adding the same treatment used before starting it may be unsafe. Report new symptoms and follow the team’s instructions about assessment rather than adjusting treatment from a laboratory result yourself. This guide makes an approval claim only for the United States because current European Union and United Kingdom marketing authorization was not established in the official records reviewed. ²⁴

Gene therapy: benefits, limits and follow-up

Adeno-associated viral-vector gene therapy aims to enable the liver to produce factor IX after a single infusion. The decision involves more than whether the infusion can be given. The World Federation of Hemophilia’s gene-therapy guideline emphasizes shared decision-making, liver assessment, coordinated specialist care and long-term follow-up. Response and durability vary, and future factor treatment may still be needed. Repeat dosing is not an established fallback if the result is inadequate or later declines. Discuss the commitments before treatment: follow-up appointments, blood tests, communication between the treating and local centers, and possible management of immune or liver-related effects. The team should also explain uncertainties without presenting a theoretical long-term risk as a proven outcome. Participation in structured long-term monitoring helps characterize benefits and risks that short trials cannot settle. A single infusion is therefore not a promise of permanent cure or freedom from future medical care. Personal priorities, expectations and support needs belong in the decision alongside laboratory eligibility. ¹⁵

Hemgenix, or etranacogene dezaparvovec, has a United States indication for adults with hemophilia B who use factor IX prophylaxis, have current or previous life-threatening bleeding, or have repeated serious spontaneous bleeds. The current selection requirements exclude people with current or previous factor IX inhibitors and include liver assessment and screening for active hepatitis B or C. European Union eligibility is adults with severe or moderately severe B without an inhibitor history. Eligibility is not established by age and diagnosis alone: a specialist center must assess the complete medical picture and discuss expected benefit and risk. Infusion reactions and liver toxicity can occur. Liver cancer from vector integration is a potential long-term risk, not a proven treatment-caused outcome. Patients need continued factor activity and liver monitoring, and may still need factor replacement according to their response and circumstances. Regulatory approval does not establish immediate supply, funding or a place in a treatment program. ²⁵

Beqvez, also known by the former EU name Durveqtix, should not be listed as a currently available alternative: the FDA Purple Book records discontinued and voluntarily revoked status, and EU authorization was withdrawn in May 2025. ²⁶

Joints, muscles and physical activity

A joint or muscle bleed can begin as warmth, tingling, tightness or discomfort before obvious swelling develops. Movement may become difficult, and a child may avoid using a limb or putting weight on it. Recognizing that early change matters because waiting for a large bruise can delay treatment. Contact the hemophilia team promptly and follow the current prescribed bleed plan. A generic set of factor-era home instructions may not suit someone using a newer preventive medicine. After the acute bleed has been treated, recovery still needs attention: pain settling is not always the same as strength and movement returning. Physiotherapy can guide a gradual recovery appropriate to the affected joint or muscle. Persistent or worsening symptoms need reassessment rather than repeated assumptions that the original bleed is resolving normally. Avoid forcing movement through pain or choosing a return-to-sport date from a general online article. The treating team can distinguish acute treatment needs from later rehabilitation goals. ¹⁰

Long-term joint care looks at function as well as the number of reported bleeds. A physiotherapist familiar with hemophilia can assess movement, muscle strength, balance and the effects of pain, then help choose appropriate exercise and rehabilitation. A joint-health score records physical findings; it is not interchangeable with a bleeding diary and does not by itself answer every question about structural joint disease. Good bleeding control remains important, but established joint problems may still need attention. Activity planning should reflect the person’s joint condition, treatment protection and the demands of the activity rather than a blanket instruction to avoid exercise. Physiotherapy may also help prepare for surgery or support recovery afterward. If everyday tasks are becoming harder, describe the specific change, such as reduced walking tolerance or difficulty bending a joint. That information helps the team set practical goals and judge whether the plan is improving function, not merely producing a reassuring number at an appointment. ⁹

Procedures, medicines, vaccinations and dental care

Tell the hemophilia team before surgery, dental procedures, biopsy or endoscopy, including procedures described as minor. The team and procedural clinician need an agreed bleeding-management plan and a way to communicate if the course changes. An emergency department should also know the diagnosis and current treatment; medical identification and an up-to-date treatment letter can help. Check new prescriptions, over-the-counter products and supplements with a clinician familiar with the bleeding disorder. Aspirin and nonsteroidal anti-inflammatory drugs can increase bleeding risk, so they should not be started casually for pain. However, do not independently stop an essential prescribed medicine, including an antithrombotic prescribed for another condition: the competing risks require coordinated advice. The aim is to choose appropriate pain relief and other treatment with the relevant clinicians informed. Keep the medicine list current, because a procedure plan written before a change in preventive treatment may need review. ⁶

Vaccinations

A bleeding disorder is a reason to plan vaccination carefully, not a general reason to miss it. Tell the vaccination provider about hemophilia and the treatment you receive. A clinician familiar with your bleeding risk can decide whether an intramuscular vaccine can be given safely and coordinate suitable timing and precautions. Automatically changing every vaccine to a subcutaneous injection is not appropriate because the recommended route depends on the vaccine. The vaccination team and hemophilia service should agree the approach rather than leaving a family to improvise it at the appointment. If previous injections caused troublesome bleeding, explain what happened so the plan can take it into account. Routine immunization can remain part of ordinary preventive care while the bleeding risk is managed individually. ²

Teeth and gums

Preventive dental care helps reduce tooth decay, gum disease and the need for more invasive treatment. Regular toothbrushing and dental review are therefore useful parts of living with a bleeding disorder, rather than something to avoid for fear of provoking bleeding. Tell the dentist about hemophilia B and provide the hemophilia service’s contact details. If treatment beyond routine care is needed, the dentist and specialist team can coordinate the plan. Necessary dental treatment is possible; the important step is advance communication about what will be done and what support is needed. Parents can help children build ordinary oral-care habits while ensuring the dental team knows the diagnosis. Ask for advice if gum bleeding or discomfort makes cleaning difficult rather than simply abandoning oral care. The specific preventive advice should match the child’s age and dental needs, while any invasive procedure has its own bleeding-management arrangements. ²⁹

Home care, school and growing independence

Families can learn to recognize bleeding, understand the treatment plan and, where appropriate, give prescribed treatment at home through supervised training. Home treatment is a skill supported by the specialist service, not a requirement that every family immediately become confident with injections. Review continues even when a child seems well because growth, activities and treatment needs change. Nursery and school staff need clear information about the child’s condition, emergency contacts and what to do after an injury or suspected bleed. A written plan is more useful than a general warning that the child has a bleeding disorder. It can support appropriate participation while helping adults recognize when to seek advice. Keep communication open as the child moves classes, changes school or starts new activities. Children and carers also need opportunities to raise practical difficulties with treatment, rather than feeling that reporting a problem means they have failed. Training and support can be revisited as needs evolve. ¹¹

Transition to adult care should build skills gradually, rather than treating one birthday as the point when all support disappears. Young people can begin taking a larger role in appointments, learning the names and purposes of medicines, recognizing their own warning signs and knowing how to contact the team. Understanding the emergency plan matters even when routine prevention has made bleeds uncommon. The pediatric and adult services can arrange a supported handover and opportunities to meet the new team. Parents or carers may remain important partners while responsibilities shift. Practical independence includes asking questions when instructions are unclear, explaining the condition to a new clinician, and speaking openly about treatment difficulties or changing activities. It does not require managing every problem alone. The pace should fit the young person’s confidence and circumstances, with gaps in knowledge addressed before they become gaps in care. A clear transfer plan helps preserve continuity during other changes in education, work and living arrangements. ¹³

Travel and treatment continuity

Arrange travel with enough time to discuss treatment supplies and emergency access with the hemophilia team. A treatment letter can explain the diagnosis, medicines and equipment, while destination planning can identify a suitable specialist service if help is needed. Carry prescribed supplies in hand luggage where permitted, in their original packaging, and check the travel and customs requirements that apply to the destination. Storage instructions differ between products, so use the actual medicine’s label rather than a general temperature rule. Travel insurance should cover the pre-existing bleeding disorder and the planned activities. Discuss how to maintain the prescribed plan across the journey and what to do if supplies are lost, delayed or damaged. Do not assume the same brand or specialist service will be readily available abroad. Planning for continuity is particularly useful when a journey involves several destinations, long transfers or places far from medical care. ¹²

Living well with ongoing specialist support

The emotional demands of hemophilia can change over time. Treatment burden, persistent pain, fear of bleeding, body confidence, relationships and family planning can all be reasonable topics for a clinical conversation. A person may look well while finding the routine demanding, or feel anxious about a new treatment even when its potential benefits are appealing. Psychological support within or alongside a hemophilia service can help address these experiences as part of comprehensive care. It is not reserved for people who are visibly struggling or have reached a crisis. Children, parents and adults may need different kinds of support at different stages, including around transition or a change in health. Tell the team what is interfering with sleep, confidence, participation or relationships so they can discuss appropriate help. Availability varies by service, but asking makes the need visible and allows the team to explain local options. The goal is care that supports daily life as well as bleeding control. ³⁰

Frequently asked questions

Can women have hemophilia B? ⁷

Yes. Women can have reduced factor IX activity and bleeding. ⁷

Is gene therapy a guaranteed cure? ²⁵

No. Response varies, and ongoing monitoring remains necessary. ²⁵

The original background video is retained below and has not been fully reviewed. Use the dated medicine information above when checking current treatment indications.